BioFocus, based at the heart of the Cambridge UK science & technology cluster, is partnering Japanese pharmaceutical giant Ono in a drug discovery programme targeting disorders of the Central nervous system (CNS).

Abcodia, the Cambridge Uk technology company engaged in the advancement of biomarkers for cancer screening, is seeking partners involved in biomarker development for the early diagnosis and screening of lung cancer.

An encouraging Phase III study by Novartis using technology from Vectura in Cambridge UK promises early commercialisation in the US, EU and Japan of a drug to combat the effects of COPD – one of the most common lung diseases.

Cambridge Healthcare has clinched an exclusive partnership agreement with Microsoft Health UK that sees its award winning ‘How are you?’ health record technology integrated with Microsoft’s HealthVault platform.

The effectiveness of novel vaccines to improve child healthcare could be tested more rapidly using Cambridge UK technology.

A blood glucose monitor concept for diabetics that has a third of the environmental impact of traditional devices has been developed by UK tech design hothouse, Cambridge Consultants.

A Cambridge UK startup whose technology helps people monitor early signs of skin cancer through their mobile, tablet or online is set for rollout in the UK and Australasia early next year.

Cambridge UK pharma company Vectura is drawing down the first development milestone payment – $3 million – in September from a US customer involved in commercialising its VR315 asthma/COPD programme.

A major US research centre has taken Cambridge UK technology to boost complex exploration of mutations in cancers.

Clinicians are signing up to a Cambridge UK initiative designed to improve the medical technology industry.

A Cambridge health technology pioneer has opened a new UK office at the heart of London’s Silicon Roundabout as it ramps up headcount to meet global demand.

Cambridge UK life science neighbours Domainex and Horizon Discovery are collaborating on new oncology initiative.

Endomagnetics, the Cambridge UK company developing magnetic technology for use in breast cancer research, reveals that it is using a new government cash award to explore melanoma detection – in partnership with two top UK hospitals.

Lab21 co-founder Dr Berwyn Clarke has been appointed a non-executive director with fellow Cambridge UK company ProteinLogic to help commercialise novel technology designed to fight TB.